References
- 1
Calabrese J R, Keck PE J r, Macfadden W, Minkwitz M, Ketter T A, Weisler R H, Cutler A J,
McCoy R, Wilson E, Mullen J, and The BOLDER Study G roup.
A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment
of bipolar I or II depression.
Am J Psychiatry.
2005;
162(7)
1351-60
- 2
Grohmann R, Engel R R, Geissler K H, Ruther E.
Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data
from the AMSP study.
Pharmacopsychiatry.
2004;
37 Suppl 1
S27-S38
- 3
Kupka R, Luckenbaugh D, Post R, Leverich G, Nolen W.
Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies.
J Clin Psychiatry.
2003;
64
1483-1494
- 4 Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine monotherapy for mania
associated with bipolar disorder: combined analysis of two international, double-blind,
randomised, placebo-controlled studies. Curr Med Res Opin 2005: in press
- 5
Vieta E, Parramon G, Padress E. et al .
Quetiapine in the treatment of rapid cycling bipolar disorder.
Bipolar Disord.
2002;
4
335-340
- 6
Yatham L N, Paulsson B, Mullen J, Vågerö M.
Quetiapine versus placebo in combination with lithium or divalproex for the treatment
of bipolar mania.
J Clin Psychopharmacol.
2004;
24
599-606
- 7
Yildiz A, Sachs G.
Characteristics of rapid cycling bipolar-I patients in a bipolar specialty clinic.
J Affect Disord.
2004;
79
247-251
Jens M. Langosch, MD
Department of Psychiatry
Center for the Innovative Treatment of Bipolar Disorder
Hauptstrasse 5
D-79104 Freiburg
Germany
Email: jens_langosch@psyallg.ukl.uni-freiburg.de
